Appointment of Joint Corporate Broker
Sareum Holdings PLC announced the appointment of Singer Capital Markets as Joint Corporate Broker, effective immediately. Strand Hanson Limited will remain the company's Nominated Adviser. Oberon Capital will also continue its role as Joint Corporate Broker. The company is a clinical-stage biotechnology company focused on developing next-generation kinase inhibitors for autoimmune disease and cancer. Sareum's lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1 and is a potential treatment for autoimmune diseases.
Select text to share a quote on X · sign in to keep highlights & notes in your SAR notes
Cambridge, UK, 30 October 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce the appointment of Singer Capital Markets as Joint Corporate Broker with immediate effect. Strand Hanson Limited remains as the Company's Nominated Adviser, and Oberon Capital as Joint Corporate Broker.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.